Using a clinical trial originally designed for safety to support an efficacy superiority claim poses unique challenges that can make reliance upon a single study for regulatory purposes potentially risky.
That was one take-home message from the US Food and Drug Administration's Endocrinologic and Metabolic Drugs Advisory Committee's June 28...




